Skip to main content
AAO-HNSF 2023 Annual Meeting & OTO Experience Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Rate ePoster

Otology/Neurotology

(330) Neuromodulation for Treatment of Tinnitus: A Systematic Review and Meta-analysis

Monday, October 2, 2023
2:45 PM – 3:45 PM East Coast USA Time
Has Audio

    Presenting Author(s)

  • LH

    Luke D. Heiland, BS

    Clinical Research Fellow
    Medical University of South Carolina
    Paradise Valley, Arizona, United States

    • Co-Author(s)

  • JO

    Johnny M. Owen, III, BS

    Medical University of South Carolina, South Carolina, United States

  • SN

    Shaun A. Nguyen, MD, FAPCR

    Professor- Director of Clinical Research
    Medical University of South Carolina
    Charleston, South Carolina, United States

  • Robert F. Labadie, MD, PhD

    Professor and Chair
    Medical University of South Carolina
    Charleston, SC, United States

  • Paul R. Lambert, MD

    Professor and Chair
    Medical University of South Carolina
    Charleston, South Carolina, United States

    • Senior Author(s)

  • Ted A. Meyer, MD PhD

    Professor
    Medical University of South Carolina
    Charleston, South Carolina, USA

Disclosure(s):
Luke D. Heiland, BS: No relevant relationships to disclose.
Shaun A. Nguyen, MD, FAPCR: No relevant relationships to disclose.


Introduction: To evaluate the treatment efficacy of electric neuromodulation versus placebo for the treatment of tinnitus.

Methods: The Cochrane Library, CINAHL, PubMed, and Scopus were searched from inception through June 2023 for English language articles documenting “neuromodulation” and “tinnitus” stratified by placebo-controlled randomized control trials with 40 or more patients. Data collected included Beck Depression Inventory (BDI), Tinnitus Handicap Inventory (THI), Tinnitus Questionnaire (TQ), and Visual Analogue Scale (VAS). A meta-analysis of continuous measures (mean), mean difference (Δ), and proportions (%) were conducted.

Results: A total of 15 randomized control trials (N=1,001) were included. The mean age was 48.4 years (range: 19-74 years), mean duration of tinnitus was 34.1 months ([17.2 to 50.9], p < 0.0001), 58.6% males ([47.7 to 69.1], p < 0.0001), and 68.4% ([45.4 to 87.5], p < 0.0001) had unilateral tinnitus. The effect of neuromodulation versus placebo on THI score is -8.8 ([-14.5 to -3.1], p = 0.002) at 1 week, -6.0 ([-8.9 to -3.1], p < 0.0001) at 1 month, and -6.3 ([-15.4 to 2.7], p = 0.17) at 6 months.

Conclusions: Our findings suggest that the effect of neuromodulation compared to placebo reaches significant benefit both in the short and long term, as measured by the THI.